127 related articles for article (PubMed ID: 32812315)
1. Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Oshita M; Ohkawa K; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2020 Nov; 50(11):1275-1283. PubMed ID: 32812315
[TBL] [Abstract][Full Text] [Related]
2. Development of a Model to Predict Liver Decompensation prior to Transarterial Chemoembolization Refractoriness in Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ferreira-Silva J; Costa-Moreira P; Cardoso H; Liberal R; Pereira P; Macedo G
GE Port J Gastroenterol; 2023 Jan; 30(1):29-37. PubMed ID: 36743988
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
[TBL] [Abstract][Full Text] [Related]
4. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Urabe A; Shigekawa M; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2020 Mar; 50(3):365-373. PubMed ID: 31661722
[TBL] [Abstract][Full Text] [Related]
5. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
6. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; An C; Sun HL; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Int J Hyperthermia; 2019; 36(1):841-853. PubMed ID: 31452408
[No Abstract] [Full Text] [Related]
7. Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria.
Saito N; Nishiofuku H; Sato T; Maeda S; Minamiguchi K; Taiji R; Matsumoto T; Chanoki Y; Tachiiri T; Kunichika H; Marugami N; Tanaka T
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174075
[TBL] [Abstract][Full Text] [Related]
8. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma.
Fukushima T; Morimoto M; Kobayashi S; Ueno M; Sano Y; Kawano K; Asama H; Nagashima S; Maeda S
Mol Clin Oncol; 2021 Jun; 14(6):119. PubMed ID: 33903825
[TBL] [Abstract][Full Text] [Related]
9. Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function.
Saito N; Tanaka T; Nishiohuku H; Sato T; Masada T; Matsumoto T; Anai H; Sakaguchi H; Sueyoshi S; Marugami N; Kichikawa K
Hepatol Res; 2020 Oct; 50(10):1176-1185. PubMed ID: 32721060
[TBL] [Abstract][Full Text] [Related]
10. Child-Pugh grade deterioration stratified by the etiology after transcatheter arterial chemoembolization as initial treatment for hepatocellular carcinoma.
Yoshitomi K; Hayashi T; Oe S; Shibata M; Honma Y; Harada M; Kooka Y
Sci Rep; 2024 Feb; 14(1):3707. PubMed ID: 38355630
[TBL] [Abstract][Full Text] [Related]
11. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization.
Yasui Y; Tsuchiya K; Kurosaki M; Takeguchi T; Takeguchi Y; Okada M; Wang W; Kubota Y; Goto T; Komiyama Y; Higuchi M; Takaura K; Hayashi T; Takada H; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Enomoto N; Himeno Y; Izumi N
Hepatol Res; 2018 May; 48(6):442-450. PubMed ID: 29278654
[TBL] [Abstract][Full Text] [Related]
12. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
[TBL] [Abstract][Full Text] [Related]
13. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.
Yoo SH; Jang JW; Kwon JH; Jung SM; Jang B; Choi JY
Clin Mol Hepatol; 2016 Dec; 22(4):458-465. PubMed ID: 28081589
[TBL] [Abstract][Full Text] [Related]
14. The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria.
Takaya H; Namisaki T; Takeda S; Kaji K; Ogawa H; Ishida K; Tsuji Y; Takagi H; Ozutsumi T; Fujinaga Y; Furukawa M; Kitagawa K; Nishimura N; Sawada Y; Shimozato N; Kawaratani H; Moriya K; Akahane T; Mitoro A; Yoshiji H
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768358
[TBL] [Abstract][Full Text] [Related]
15. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma.
Tsai YJ; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiang JH; Huo TI; Lee SD
Hepatol Int; 2011 Dec; 5(4):975-84. PubMed ID: 21533669
[TBL] [Abstract][Full Text] [Related]
16. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.
Hsu KF; Chu CH; Chan DC; Yu JC; Shih ML; Hsieh HF; Hsieh TY; Yu CY; Hsieh CB
Eur J Radiol; 2012 Mar; 81(3):466-71. PubMed ID: 21376495
[TBL] [Abstract][Full Text] [Related]
17. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
Carling U; Røsok B; Line PD; Dorenberg EJ
Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
[TBL] [Abstract][Full Text] [Related]
18. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
Wang TC; An TZ; Li JX; Zhang ZS; Xiao YD
Front Mol Biosci; 2021; 8():633590. PubMed ID: 33816555
[No Abstract] [Full Text] [Related]
20. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
